Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy
Source: SeekingAlpha
2025-03-04 10:21:40 ET
Summary
- Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval.
- AUTL has $657.1 million in cash, providing a cash runway of approximately 3 years, alleviating immediate financial concerns.
- The company faces significant competition in the CD19 CAR T-cell therapy market, making sales execution crucial for success.
- Despite the competitive landscape, AUTL's broad pipeline and recent approval of obe-cel position it well for future growth.
Topline Summary and Update
Read the full article on Seeking Alpha
For further details see:
Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy
Autolus Therapeutics plc
NASDAQ: AUTL
AUTL Trading
22.54% G/L:
$1.93 Last:
4,124,476 Volume:
$1.62 Open:
AUTL Latest News
May 14, 2026 07:00:00 am
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesMay 05, 2026 07:00:00 am
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026April 29, 2026 04:05:00 pm
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionAUTL Stock Data
$387,238,481
109,839,996
N/A
49
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
